ASX:CUV Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Clinuvel Pharmaceuticals Stock (ASX:CUV) 30 days 90 days 365 days Advanced Chart Get CUV alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume124,193 shsAverage VolumeN/AMarket CapitalizationA$563.18 millionP/E Ratio15.95Dividend Yield0.44%Price TargetN/AConsensus RatingN/A Company Overview Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia. Read More Receive CUV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CUV Stock News HeadlinesUndervalued ASX biotechJuly 8, 2025 | morningstar.com.auMClinuvel Pharmaceuticals Limited's (ASX:CUV) top owners are individual investors with 60% stake, while 23% is held by institutionsJuly 6, 2025 | finance.yahoo.comMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.July 18 at 2:00 AM | Crypto Swap Profits (Ad)CUV News, Analysis, Announcements & Results | Clinuvel Pharmaceuticals Limited | AFR - Financial ReviewJune 25, 2025 | afr.comClinuvel Pharmaceuticals Stock Price HistoryMay 28, 2025 | investing.comClinuvel Pharmaceuticals Limited: CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105May 7, 2025 | finanznachrichten.deBiocurious: FDA approval remains the Holy Grail for ASX life science stocksMarch 18, 2025 | msn.comHigh Growth Tech Stocks In Australia For March 2025March 16, 2025 | finance.yahoo.comSee More Headlines CUV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Clinuvel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clinuvel Pharmaceuticals investors own include Cochlear (COH), CSL (CSL), ResMed (RMD), ARB (ARB), Accent Group (AX1), Corporate Travel Management (CTD) and Mineral Resources (MIN). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CUV CIKN/A Webwww.clinuvel.com Phone61 3 9660 4900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A$0.70 Trailing P/E Ratio15.95 Forward P/E RatioN/A P/E GrowthN/ANet IncomeA$35.64 million Net Margins40.67% Pretax MarginN/A Return on Equity18.67% Return on Assets14.29% Debt Debt-to-Equity Ratio0.43 Current Ratio8.81 Quick Ratio10.03 Sales & Book Value Annual SalesA$88.18 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow19.36 Book ValueA$4.02 per share Price / BookN/AMiscellaneous Outstanding Shares50,060,000Free FloatN/AMarket CapA$563.18 million OptionableNot Optionable Beta0.92 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (ASX:CUV) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinuvel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CUV Stock Alerts